Immuron Ltd (IMRN)
2.51
-0.02
(-0.59%)
USD |
NASDAQ |
May 07, 16:00
Immuron Revenue (TTM): 2.349M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.349M |
| June 30, 2023 | 1.199M |
| December 31, 2022 | 0.7648M |
| June 30, 2022 | 0.5495M |
| December 31, 2021 | 0.2648M |
| June 30, 2021 | 0.1114M |
| December 31, 2020 | 0.6469M |
| Date | Value |
|---|---|
| June 30, 2020 | 1.696M |
| December 31, 2019 | 2.050M |
| June 30, 2019 | 1.688M |
| December 31, 2018 | 1.400M |
| June 30, 2018 | 1.405M |
| December 31, 2017 | 1.226M |
| June 30, 2017 | 1.047M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.1114M
Minimum
Jun 2021
2.349M
Maximum
Dec 2023
1.132M
Average
0.9819M
Median
Revenue (TTM) Benchmarks
| Mesoblast Ltd | 7.501M |
| CERo Therapeutics Holdings Inc | -- |
| Alterity Therapeutics Ltd | -0.0416M |
| Kazia Therapeutics Ltd | -- |
| Immutep Ltd | 5.113M |